Clinical integration of next generation sequencing: Coverage and reimbursement challenges

Patricia A. Deverka, Jennifer C. Dreyfus

Research output: Contribution to journalArticle

Abstract

Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.

Original languageEnglish (US)
Pages (from-to)22-41
Number of pages20
JournalJournal of Law, Medicine and Ethics
Volume42
Issue numbers1
DOIs
StatePublished - Sep 1 2014

ASJC Scopus subject areas

  • Issues, ethics and legal aspects
  • Health Policy

Fingerprint Dive into the research topics of 'Clinical integration of next generation sequencing: Coverage and reimbursement challenges'. Together they form a unique fingerprint.

  • Cite this